IRVINE, Calif., May 18, 2017 /PRNewswire/ -- Edwards Lifesciences
Corporation (NYSE: EW), the global leader in patient-focused
innovations for structural heart disease and critical care
monitoring, today announced that reports from partners in its Every
Heartbeat Matters charitable initiative demonstrate they have
impacted the global burden of heart valve disease by educating,
screening and/or treating more than 400,000 underserved individuals
since launching in 2014. Edwards believes the initiative is on
track to achieve the goal of impacting one million underserved
people by 2020.
"Millions of people around the world suffer from heart valve
disease, yet unbeknown to most, the disease is highly treatable
once detected," said Maurice E.
Sarano, M.D., professor of medicine at Mayo Medical School
and director of the Valvular Heart Disease Clinic and consultant in
Cardiovascular Diseases and International Medicine at Mayo Clinic,
who presented at the recent 2017 Every Heartbeat Matters Partner
Summit.
"Underserved heart valve patients are at a significant
disadvantage and have lower chances of receiving the care and
treatment they need to survive," said David
H. Adams, M.D., cardiac surgeon-in-chief, Mount Sinai Health
System, Marie-Josée and Henry R. Kravis Professor and chairman
Department of Cardiovascular Surgery, Icahn School of Medicine at
Mount Sinai and The Mount Sinai Hospital, and president, Mitral
Foundation, who also presented at the summit. "It's inspiring to
see the focused, strategic efforts of Every Heartbeat Matters'
partners who are bringing new solutions and boundless energy to
address this global public health issue."
Every Heartbeat Matters supports cardiac- and patient-focused
non-profit organizations through grants from Edwards Lifesciences
Foundation and donations of Edwards heart valve technologies for
indigent care. The initiative focuses on one goal: by 2020, Every
Heartbeat Matters will impact the global burden of heart valve
disease by supporting the education, screening and treatment of one
million underserved people. Investments in this initiative since
2014 total more than $15 million.
"Our Every Heartbeat Matters partners are bringing strategic
philanthropy, passion and commitment to help vulnerable people all
around the world who are affected by heart valve disease," said
Michael A. Mussallem, chairman and
CEO, Edwards Lifesciences, and chairman, Edwards Lifesciences
Foundation. "We are proud to help fuel their bold and impactful
work and are on track to achieve our collective pursuit of helping
one million underserved people by 2020."
Dr. Sarano is a consultant of Edwards Lifesciences and
Edwards Lifesciences Foundation.
Request for Proposals
Edwards Lifesciences Foundation is accepting requests for
funding from non-profit organizations to partner on programs for
its Every Heartbeat Matters initiative or those that strengthen the
communities in which Edwards' employees live and work. The
foundation's 2017 grant cycle is open May 15
to June 23, and grant applications and other information,
including a complete listing of all grants issued, are available at
www.edwards.com/corporategiving.
About Edwards Lifesciences and Edwards Lifesciences
Foundation
Edwards Lifesciences, based in Irvine,
Calif., is the global leader in patient-focused medical
innovations for structural heart disease, as well as critical care
and surgical monitoring. Driven by a passion to help
patients, the company collaborates with the world's leading
clinicians and researchers to address unmet healthcare needs,
working to improve patient outcomes and enhance lives. For more
information, visit www.edwards.com and follow us on Twitter
@EdwardsLifesci. Edwards Lifesciences Foundation focuses on
supporting underserved heart valve and critically ill patients, as
well as strengthening the communities in which Edwards employees
live and work through gifts to non-profit organizations all around
the world. Additional information can be found at
www.edwards.com/corporategiving.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to, statements by Drs.
Sarano and Adams and Mr. Mussallem and expectations regarding
achievement of the Every Heartbeat Matters goal. Forward-looking
statements are based on estimates and assumptions made by
management of the company and are believed to be reasonable, though
they are inherently uncertain and difficult to predict. Our
forward-looking statements speak only as of the date on which they
are made and we do not undertake any obligation to update any
forward-looking statement to reflect events or circumstances after
the date of the statement.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors, including but not limited to, unanticipated delays or
changes in trends for achieving the goals. These and other
additional factors are detailed in the company's filings with the
Securities and Exchange Commission including its Annual Report on
Form 10-K for the year ended December 31,
2016. These filings, along with important safety information
about our products, may be found at www.edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo and Every
Heartbeat Matters are trademarks of Edwards Lifesciences
Corporation. All other trademarks are the property of their
respective owners.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/edwards-lifesciences-every-heartbeat-matters-initiative-on-track-to-impact-1-million-underserved-people-by-2020-300459908.html
SOURCE Edwards Lifesciences Corporation